CapsoVision, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CapsoVision, Inc. (NASDAQ: CV) develops and commercializes advanced imaging and artificial intelligence-enabled capsule endoscopy solutions for the detection and diagnosis of gastrointestinal diseases. The company offers CapsoCam Plus, a wire-free, single-use capsule endoscope providing 360-degree panoramic visualization of the small bowel mucosa in adults and children aged two years and above; CapsoCam Colon for non-invasive colon imaging, polyp detection, and measurement; and CapsoColon 3D in development for large intestine applications. Complementary products and services include CapsoCloud, a cloud-based software-as-a-service platform for remote video access, download, and AI-assisted analysis; CapsoAccess, a capsule data retrieval system; CapsoView software for direct video review; CapsoRetrieve retrieval kit using magnetic technology; and capsule video reading services. CapsoVision serves gastroenterologists, medical practices, clinics, and hospitals, selling directly in the United States and through exclusive distributors internationally, with key markets in France, Germany, and Canada. The company operates globally from its headquarters in Saratoga, California, where it was incorporated in 2005, and established a direct sales team in Germany in 2023 to expand its European presence. Recent developments include the completion of an initial public offering in July 2025, raising net proceeds of $23.4 million; submission of an FDA Breakthrough Device Designation application in November 2025 for a capsule targeting early-stage pancreatic cancer detection; entry into a development agreement with Canon Inc. in 2025 for higher-resolution CMOS image sensors; appointment of David Garcia as Senior Vice President of Finance in November 2025; advancement of AI-assisted reading updates for CapsoCam Plus with planned FDA submission by end-2025; and commencement of clinical enrollment for a next-generation colon capsule.
CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D.
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
CapsoVision Q1 Earnings Call Highlights
CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript
CapsoVision Reports First Quarter 2026 Financial Results
CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026
Head to Head Comparison: Nanovibronix (NASDAQ:FEED) versus CapsoVision (NASDAQ:CV)
CapsoVision, Inc. (CV) Q4 2025 Earnings Call Transcript
CapsoVision Announces $14 Million Private Placement Financing
CapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026
Comparing Biosig Technologies (NASDAQ:STEX) and CapsoVision (NASDAQ:CV)
CapsoVision, Inc. (NASDAQ:CV) Short Interest Update
CapsoVision (NASDAQ:CV) and Profusa (NASDAQ:PFSA) Head-To-Head Review
President Trump meets with oil executives about Venezuela at White House
CapsoVision (NASDAQ:CV) Shares Gap Down – What’s Next?
CapsoVision Submits FDA 510(k) for AI-Assisted Module in CapsoCam Plus
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday
CapsoVision (NASDAQ:CV) Shares Down 6.5% – Time to Sell?
CapsoVision, Inc.’s Lock-Up Period Set To End on December 29th (NASDAQ:CV)